{"id":24419,"date":"2023-08-24T04:28:00","date_gmt":"2023-08-23T20:28:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=24419"},"modified":"2023-08-24T06:06:39","modified_gmt":"2023-08-23T22:06:39","slug":"chest%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%90%b8%e5%85%a5%e5%a6%a5%e5%b8%83%e9%9c%89%e7%b4%a0%e6%b2%bb%e7%96%97%e4%bc%b4%e9%9a%8f%e9%93%9c%e7%bb%bf%e5%81%87%e5%8d%95%e8%83%9e%e8%8f%8c","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=24419","title":{"rendered":"[Chest\u53d1\u8868\u8bba\u6587]\uff1a\u5438\u5165\u59a5\u5e03\u9709\u7d20\u6cbb\u7597\u4f34\u968f\u94dc\u7eff\u5047\u5355\u80de\u83cc\u611f\u67d3\u7684\u652f\u6c14\u7ba1\u6269\u5f20\u6210\u5e74\u60a3\u8005\u7684\u53cc\u76f2\u968f\u673a\u5b89\u6170\u5242\u5bf9\u71673\u671f\u4e34\u5e8a\u8bd5\u9a8c"},"content":{"rendered":"\n

CHEST INFECTIONS: ORIGINAL RESEARCH| VOLUME 163, ISSUE 1<\/a>, P64-76, JANUARY 2023Download Full Issue<\/p>\n\n\n\n

A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa<\/em> Infection<\/h1>\n\n\n\n

Wei-jie Guan, Jin-fu Xu, Hong Luo, et al<\/h3>\n\n\n\n

Chest 2023; 163: 64-67 Published:July 18, 2022<\/h3>\n\n\n\n

DOI:https:\/\/doi.org\/10.1016\/j.chest.2022.07.007<\/a><\/h3>\n\n\n\n

Background<\/h3>\n\n\n\n

Few large-scale studies have demonstrated the efficacy of tobramycin nebulization in bronchiectasis. We evaluated the efficacy and safety of nebulized tobramycin inhalation solution (TIS) in adults with bronchiectasis with Pseudomonas aeruginosa<\/em> infection.<\/p>\n\n\n\n

Research Question<\/h3>\n\n\n\n

Can TIS effectively reduce sputum P aeruginosa<\/em> density and improve the bronchiectasis-specific quality of life in patients with bronchiectasis with P aeruginosa<\/em> infection?<\/p>\n\n\n\n

Study Design and Methods<\/h3>\n\n\n\n

This was a phase 3, 16-week, multicenter, randomized, double-blind, placebo-controlled trial. Eligible adults with bronchiectasis were recruited from October 2018 to July 2021. On the basis of usual care, patients nebulized TIS (300 mg\/5 mL twice daily) or normal saline (5 mL twice daily) via vibrating-mesh nebulizer. Treatment consisted of two cycles, each consisting of 28 days on-treatment and 28 days off-treatment. The coprimary end points included changes from baseline in P aeruginosa<\/em> density and Quality-of-Life Bronchiectasis Respiratory Symptoms score on day 29.<\/p>\n\n\n\n

Results<\/h3>\n\n\n\n

The modified intention-to-treat population consisted of 167 patients in the tobramycin group and 172 patients in the placebo group. Compared with placebo, TIS resulted in a significantly greater reduction in\u00a0P\u00a0aeruginosa<\/em>\u00a0density (adjusted mean difference, 1.74 log10<\/sub>\u00a0colony-forming units\/g; 95%\u00a0CI, 1.12-2.35;\u00a0P<\/em>\u00a0< .001) and greater improvement in Quality-of-Life Bronchiectasis Respiratory Symptoms score (adjusted mean difference, 7.91; 95%\u00a0CI, 5.72-10.11;\u00a0P<\/em>\u00a0< .001) on day 29. Similar findings were observed on day 85. TIS resulted in a significant reduction in 24-h sputum volume and sputum purulence score on days 29, 57, and 85. More patients became culture negative for\u00a0P\u00a0aeruginosa<\/em>\u00a0in the tobramycin group than in the placebo group on day 29 (29.3%\u00a0vs\u00a010.6%). The incidence of adverse events and serious adverse events were comparable between the two groups.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Interpretation<\/h3>\n\n\n\n

TIS is an effective treatment option and has an acceptable safety profile in patients with bronchiectasis with P aeruginosa<\/em>infection.<\/p>\n\n\n\n

Trial Registration<\/h3>\n\n\n\n

ClinicalTrials.gov; No. NCT03715322; URL: www.clinicaltrials.gov<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CHEST INFECTIONS: ORIGINAL RESEARCH| VOLUME 163, I […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24419"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24419"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24419\/revisions"}],"predecessor-version":[{"id":24420,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/24419\/revisions\/24420"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}